Biotechnology
"Hong Kong Heritage Pork" brings high-quality local pork to Hong Kong through an innovative double testing method
HONG KONG, Sept. 27, 2021 /PRNewswire/ -- John Lau Hon Kit, the founder of Hong Kong Heritage Pork, worked to introduce into his own pig farm a self-breeding and self-raising, and self-sale technique that allows everyone inHong Kong to taste fresh, delicious, and safe locally raised pork.John Lau...
2021-09-27 17:30
2297
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it received IND clearance on...
2021-09-27 08:30
1503
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-09-27 08:00
4623
GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target
NANJING, China, Sept. 26, 2021 /PRNewswire/ -- On September 26, 2021, GenScript ProBio and AskGene signed a license agreement forGenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target.GenScript ProBio grants a non-exclusive global license to AskGene to use GenScrip...
2021-09-26 22:28
2633
JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
SHANGHAI, Sept. 26, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced updated 1-year follow-up result of relmacabtagene autoleucel injection (relma-cel) for t...
2021-09-26 20:00
5314
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote ...
2021-09-26 10:12
2560
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 24, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
2021-09-24 14:09
2510
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Everest Medicines
2021-09-24 13:56
4792
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
2021-09-24 09:18
4200
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
SAN FRANCISCO and SUZHOU, China, Sept. 24, 2021 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...
2021-09-24 08:00
4397
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
* Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedic...
2021-09-23 21:59
8235
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins
- Potential for superior tolerability to mRNA and Adenovirus Vector vaccines - Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), a...
2021-09-23 15:00
6937
The First US World-Class Bioscience Design Corporation Officially Launched
TAIPEI, Sept. 22, 2021 /PRNewswire/ -- TCI Co., Ltd. set up a subsidiary in the United States for the first time in 2019 to expand its business footprint and bring its successful experience inAsia to the United States. After two years of continuous effort, it has accumulated a series of extensiv...
2021-09-23 09:00
2440
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-09-23 08:00
4659
MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study
GENEVA, Sept. 23, 2021 /PRNewswire/ -- MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clin...
2021-09-23 08:00
3902
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus onLatin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 2...
2021-09-22 20:00
6572
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...
2021-09-22 18:56
2972
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seam...
2021-09-22 18:00
2344
Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research
SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced the appointment of Dr.Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect fromSeptember 20, 2021. She will report to Dr.Kevin Pan, Founder and CEO of Asieris. Alice has over 20 ...
2021-09-22 14:45
1575
New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved in Singapore to treat 2L metastatic small cell lung cancer (SCLC) in 20 years * ZEPZELCA provisional approval represents an important advance for adult patients whose metastatic SCLC has progressed on or after platinum-...
2021-09-22 14:30
2463
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 299 media titles]
2026-08-25 10:00Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
[Picked up by 291 media titles]
2026-08-25 07:00
ViewSonic Launches XG2738-2K-OLED Gaming Monitor with QD-OLED Technology and OLED Care
[Picked up by 288 media titles]
2026-08-27 10:30
Most Read
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
18351
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
13987